Show simple item record

dc.contributor.authorEvers, Andrea W M
dc.contributor.authorColloca, Luana
dc.contributor.authorBlease, Charlotte
dc.contributor.authorGaab, Jens
dc.contributor.authorJensen, Karin B
dc.contributor.authorAtlas, Lauren Y
dc.contributor.authorBeedie, Chris J
dc.contributor.authorBenedetti, Fabrizio
dc.contributor.authorBingel, Ulrike
dc.contributor.authorBüchel, Christian
dc.contributor.authorBussemaker, Jet
dc.contributor.authorColagiuri, Ben
dc.contributor.authorCrum, Alia J
dc.contributor.authorFinniss, Damien G
dc.contributor.authorGeers, Andrew L
dc.contributor.authorHowick, Jeremy
dc.contributor.authorKlinger, Regine
dc.contributor.authorMeeuwis, Stefanie H
dc.contributor.authorMeissner, Karin
dc.contributor.authorNapadow, Vitaly
dc.contributor.authorPetrie, Keith J
dc.contributor.authorRief, Winfried
dc.contributor.authorSmeets, Ionica
dc.contributor.authorWager, Tor D
dc.contributor.authorWanigasekera, Vishvarani
dc.contributor.authorVase, Lene
dc.contributor.authorKelley, John M
dc.contributor.authorKirsch, Irving
dc.date.accessioned2020-11-03T16:35:50Z
dc.date.available2020-11-03T16:35:50Z
dc.date.issued2020-10-19
dc.identifier.urihttp://hdl.handle.net/10713/14018
dc.description.abstractIntroduction: Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments. Objective: There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information. Methods: Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients. Results: There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities. Conclusions: The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients' needs, and on developing standardized disclosure training modules for clinicians.en_US
dc.description.urihttps://doi.org/10.1159/000510738en_US
dc.language.isoenen_US
dc.publisherS. Karger AGen_US
dc.relation.ispartofPsychotherapy and Psychosomaticsen_US
dc.rights© 2020 The Author(s) Published by S. Karger AG, Basel.en_US
dc.subjectDisclosureen_US
dc.subjectExpert consensusen_US
dc.subjectNocebo effectsen_US
dc.subjectPatient-clinician communicationen_US
dc.subjectPlacebo effectsen_US
dc.titleWhat Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensusen_US
dc.typeArticleen_US
dc.identifier.doi10.1159/000510738
dc.identifier.pmid33075796
dc.source.beginpage1
dc.source.endpage8
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record